XBiotech Inc Stock
€2.42
Your prediction
XBiotech Inc Stock
Pros and Cons of XBiotech Inc in the next few years
Pros
Cons
Performance of XBiotech Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| XBiotech Inc | -3.970% | -3.200% | 1.681% | -62.188% | -32.402% | -55.596% | -80.164% |
| Krystal Biotech | 3.450% | 8.104% | -2.200% | -18.967% | -21.124% | 135.392% | - |
| Ardelyx Inc. | 3.180% | -0.371% | -7.034% | -47.866% | -35.045% | 436.606% | -47.561% |
| Evolus Inc | -2.350% | 4.403% | -18.627% | -27.193% | -20.952% | -30.252% | 80.435% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Evaluating the financial health of XBiotech, a company operating in the Biotechnology and Medical Research sector, reveals a landscape filled with both challenges and opportunities. Despite the promising advancements in biotechnology and medical research, XBiotech’s recent financial performance paints a complex picture. The negative trends in income and cash flow suggest potential struggles in operational execution and revenue generation, while certain metrics indicate strengths that offer a glimpse of resilience.
Strong Cash Position: XBiotech maintains a robust cash balance, reported at approximately $200 million as of December 31, 2023. This significant cash reserve provides a cushion for operational needs, research investments, and potential unforeseen expenditures. It can also support future growth initiatives, such as clinical trials or acquisitions.
Total Stockholder Equity: As of the latest balance sheet, total stockholder equity stands at approximately $218.8 million. This indicates a strong equity base, reflecting the confidence of shareholders and investors in the company's long-term prospects. A high equity position can also imply lower financial risk since the company relies less on debt financing.
